The healthy heart relies primarily upon the oxidation of fatty acids for energy, with the remaining coming from the oxidation of glucose and lactate. Changes in energy requirements are met by altering the balance of fuels depending upon the hormonal milieu as well as upon the availability of oxygen and substrates. The use of carbohydrates for fuel is metabolically more efficient and may improve the coupling between glycolysis and pyruvate oxidation. Therefore, promoting a shift in metabolic fuel substrate use during times of reduced oxygen availability may represent a cardioprotective strategy. Subsequently, there has been interest in pharmacologic strategies such insulin or drugs like ranolazine and dichloroacetate that stimulate carbohydrate oxidation either by enhancing oxidation at the pyruvate dehydrogenase complex or by limiting fatty acid oxidation. There is evidence that nutrients may also be able to stimulate carbohydrate oxidation. Previous studies by our group suggest that a combination of nutrients (carnitine, coenzyme Q10, and taurine) may work together, resulting in pleiotropic cardioprotective effects. Our current studies are investigating the potential of nutrients as both a preventative and adjunctive treatment before and after an ischemic event. These investigations will determine the role of nutritional supplementation in the care of patients with ischemic injury.
Get full access to this article
View all access options for this article.
References
1.
Freeman L, Roubenoff R: The nutrition implications of cardiac cachexia. Nutr Review52:340-347, 1994.
2.
Regitz V, Shug AL, Fleck E: Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and coronary, hypertensive and valvular heart diseases. Am J Cardiol65:755-760, 1990.
3.
Suleiman MS, Fenando HC, Dihmis WC: A loss of taurine and other amino acids from ventricles of patients undergoing bypass surgery. Br Heart J69:241-245, 1993.
4.
Folkers K, Vadhanavikit S, Mortensen SA: Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. PNAS82:901-904, 1985.
5.
Keith M, Geranmayegan A, Sole MJ, et al: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol31:1352-1356, 1998.
6.
Lopaschuk GD, Belke DD, Gamble J, et al: Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta1213:263-276, 1994.
7.
Kissling G: Oxygen consumption and substrate uptake of the hypertrophied rat heart in situ. Basic Res Cardiol75:185-192, 1980.
8.
Lopaschuk GD, Stanley WC: Glucose in the ischemic heart. Circulation95:313-315, 1997.
9.
McNully PH, Sinusas AJ, Shi CQ, et al: Glucose metabolism distal to a critical coronary stenosis in a canine model of low flow ischemia. J Clin Invest98:62-69, 1996.
10.
Rao V, Merante F, Shirai T, et al: Insulin stimulate pyruvate dehaydrogenase and protects human ventricular myocytes from simulated ischemia. J Thorac Cardiovasc Surg116:485-494, 1998.
Lango R, Smolenski RT, Narkiewicz M, et al: Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res51:21-29, 2001.
13.
Pearson DJ, Tubbs PK: Carnitine and derivatives in rat tissues. Biochem J105:953-963, 1967.
14.
Lysiak W, Lilly K, Dilisa F, et al: Quanitification of the effect of L-carnitine on the levels of acid soluble short chain acyl CoA and CoASH in rat heart and liver mitochondria. J Biol Chem263:1511-1516, 1988.
15.
Lysiak W, Toth PP, Suelter CH, et al: Quantification of the efflux of acylcarnitines from rat heart, brain and liver mitochondria. J Biol Chem261:13696-13703, 1986.
16.
Broderick TL, Quinney HA, Barker CC, et al: Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation87:972-981, 1993.
17.
Arsenian MA: Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis40:265-286, 1997.
18.
Pepine CJ: The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther13:2-18, 1991.
19.
Schonekess, Allard M, Lopaschuk GD: Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circulation Res77:726-734, 1995.
20.
Cherchi A, Lat C, Trucco G, et al: Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicentre, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharm Ther Tox23:569-572, 1985.
21.
Broderick T, Quinney HA, Lopaschuk GD: Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem267:3758-3763, 1992.
22.
Pastoris O, Dossena M, Foppa P, et al: Effect of L-carnitine on myocardial metabolism: Results of a balanced, placebo-controlled, double-blind study in patients undergoing open heart surgery. Pharm Res37(2):115-122, 1998.
23.
Raschke P, Massoudy P, Becker B: Taurine protects the heart from neutrophil-induced reperfusion injury. Free Rad Biol Med19:461-471, 1995.
24.
Hamaguchi T, Azuma J, Schaffer S: Interaction of taurine and methionine: Inhibition of myocardial phospholipids methyltransferase. J Cardiovasc Pharmacol18:224-230, 1991.
25.
Pion PD, Kittleson MD, Rogers QR, et al: Myocardial failure in cats associated with low plasma taurine: A reversible cardiomyopathy. Science237:764-768, 1987.
26.
Rasmusson RL, Davis DG, Lieberman M: Amino acid loss during volume regulatory decrease in culture chick heart cells. Am J Physiol264:C136-C145, 1993.
27.
Azuma J, Sawamura A, Awata N: Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J56:95-99, 1992.
28.
Satoh H, Sperelekis N: Review of some actions of taurine on ion channels of cardiac muscle cells and some others. Gen Pharmacol30:451-463, 1998.
29.
Cunningham C, Tipton KF, Dixon HBF: Conversion of taurine into N-chlorotaurine (taurine chloramine) and sulphoacetaldehyde in response to oxidative stress. Biochem J330-939-945, 1998.
30.
Crass MF III, Lombardini JB: Loss of cardiac muscle taurine after acute left ventricular ischemia. Life Sci21:951-958, 1977.
31.
Lake N: Alterations of ventricular contractility and myofibrillar loss in taurine deficient hearts. Adv Exp Med Biol359:335-342, 1994.
32.
Takihara K, Azuma N, Awata H, et al: Beneficial effect of taurine in rabbits with congestive heart failure. Am Heart J112:1278-1284, 1986.
33.
Milei J, Ferreira R, Llesuy S, et al: Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularization. Am Heart J123:339-345, 1992.
34.
Kramer JH, Chovan JP, Schaffer SW: The effect of taurine on calcium paradox and ischemic heart failure. Am J Physiol240:H238-H246, 1981.
35.
Azari J, Brumbaugh P, Barbeau A, et al: Taurine decreases lesion severity in the hearts of cardiomyopathic hamsters. Can J Neurol Sci7:435-440, 1980.
36.
Welty MC, Welty JD, McBroom MJ: Effect of isoproterenol and taurine on heart calcium in normal and cardiomyopathic hamsters. J Mol Cell Cardiol14:353-357, 1982.
37.
Franconi F, Stendardi I, Matucci R, et al: A protective effect of taurine on hypoxic and reoxygenated guinea pig heart. In: Oja SS, Ahtee L, Kontro P, Paasonen MK, eds. Taurine: Biological Actions and Clinical perspectives. New York: Alan R. Liss Inc.1985:177-182.
38.
Sawamura A, Azuma J, Harada H, et al: Protection by oral taurine pretreatment against negative inotropic effects of low calcium medium on isolated perfused chick hearts. Cardiovasc Res17:620-626, 1983.
39.
Azari J, Brumbaugh P, Huxtable R: Prophylaxis by taurine in the hearts of cardiomyopathic hamsters. J Mol Cell Cardiol12:1353-1366, 1980.
40.
Milei J, Ferreira R, Llesuy S, et al: Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularization. Am Heart J123:339-345, 1992.
41.
Folkers K, Langsjoen P, Langsjoen PH: Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun182:247-253, 1992.
42.
Keith ME, Ball A, Jeejeebhoy KN, et al: Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. Can J Cardiol17:449-458, 2001.
43.
Jeejeebhoy F, Keith M, Barr A, et al: Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J143:1092-1100, 2002.
44.
Guarnier C, Muscari C, Manfroni S, et al: The treatment with coenzyme Q10 the mitochondrial function and superoxide radical formation in cardiac muscle hypertrophied by mild aortic stenosis. J Mol Cell Cardiol19:63-71, 1987.
45.
Langsjoen PH, Vadhanavikit S, Folkers K: Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA82:4240-4244, 1985.
46.
HoffmanBang C, Renqvist N, Swedburg K, et al for the Q10 study group: Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Failure1:101-107, 1995.
47.
Watson PS, Scalia GM, Galbraith A, et al: Lack of effect of coenzyme Q10 on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol33:1549-1552, 1999.
48.
Soja AM, Mortensen SA: Treatment of congestive heart failure with coenzyme Q10 illuminated meta-analysis of clinical trials. Mol Aspects Med18:S159-S168, 1997.
49.
Khatta M, Alexander BS, Krichten CM, et al: The effect of coenzyme Q10 in patients with congestive heart failure. Ann Int Med132:636-640, 2000.
50.
Crestanello JA, Kamelgard J, Lingle DM, et al: Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment. J Thorac Cardiovasc Surg111:443-450, 1996.
51.
Maulik N, Yoshida T, Engelman RM, et al: Dietary coenzyme Q10 supplement renders swine hearts resistant to ischemiareperfusion injury. Am J Physiol278:H1084-H1090, 2000.
